Search | Page 3 | Aplastic Anemia and MDS International Foundation

Search

Search results

  1. Prospective assessment of effects on iron-overload parameters of deferasirox therapy in patients with myelodysplastic syndromes.

    ... Greenberg PL, Koller CA, Cabantchik ZI, Warsi G, Glynos T, Paley C, Schiffer C Original ... 52 weeks of therapy despite ongoing receipt of red blood cell transfusions. Bone ...

    Research Article last updated 07/20/2018 - 5:14pm.

  2. Outcomes in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with isolated deletion 5q treated with lenalidomide: a subset analysis from the MDS-004 study

    ... B, Ganser A, Bowen D, Schlegelberger B, Göhring G, Fu T, Benettaib B Original Publication ... respectively. RESULTS: Rates of red blood cell - transfusion independence (RBC-TI) ≥182 days were higher in ...

    Research Article last updated 07/20/2018 - 5:15pm.

  3. Oral Azacitidine (CC-486) for the Treatment of Myelodysplastic Syndromes and Acute Myeloid Leukemia

    ... Author(s):  Cogle CR, Scott BL, Boyd T, Garcia-Manero G Original ... therapy for patients with AML not eligible for stem cell transplant , and as maintenance therapy for patients with MDS or AML ...

    Research Article last updated 07/20/2018 - 5:15pm.

  4. Efficacy and safety of extended dosing schedules of CC-486 (oral azacitidine) in patients with lower-risk myelodysplastic syndromes

    ... A, Cogle CR, Edenfield WJ, Hetzer J, Kumar K, Laille E, Shi T, MacBeth KJ, Skikne B Original ... Response (complete or partial remission, red blood cell [RBC] or platelet transfusion independence [TI], or ...

    Research Article last updated 07/20/2018 - 5:15pm.

  5. MDS - Treatment (OLD)

    ... May or may not need blood transfusions, depending on blood cell counts Have a low or intermediate-1 risk IPSS score, which is between ... bone marrow to make more red blood cells. If you don't have enough natural EPO or if you have anemia, your doctor may prescribe a ...

    Topic section last updated 07/20/2018 - 5:15pm.

  6. Impact of the revised International Prognostic Scoring System cytogenetics and monosomal karyotype on outcome after allogeneic stem cell transplantation for myelodysplastic syndromes and secondary acute myeloid leukemia evolving from myelodysplastic syndr

    ... M, Passweg J, Cornelissen J, Beelen D, Heuser M, de Witte T, Kröger N Original Publication ... classification on outcome after allogeneic stem cell transplantation in patients with myelodysplastic syndromes or ...

    Research Article last updated 07/20/2018 - 5:15pm.

  7. Immune markers of disease severity and treatment response in pediatric acquired aplastic anemia

    ... with aplastic anemia (AA) and explore PNH-status, T-regulatory and NK-cell frequency as potential markers of clinical response. METHODS: Data ...

    Research Article last updated 07/20/2018 - 5:14pm.

  8. A combination of fludarabine, half-dose cyclophosphamide, and anti-thymocyte globulin is an effective conditioning regimen before allogeneic stem cell transplantation for aplastic anemia

    ... Ashizawa M, Akahoshi Y, Nakano H, Ugai T, Wada H, Yamasaki R, Ishihara Y, Kawamura K, Sakamoto K, Sato M, Terasako K, ... been investigated for use in allogeneic hematopoietic stem cell transplantation (allo-HSCT) in patients with aplastic anemia to ...

    Research Article last updated 07/20/2018 - 5:15pm.

  9. The small population of PIG-A mutant cells in myelodysplastic syndromes do not arise from multipotent hematopoietic stem cells

    ... cells arising from a multipotent hematopoietic stem cell acquiring a PIG-A mutation . Many patients with aplastic anemia ... deficient progenitor cells, a novel T lymphocyte enrichment culture assay with proaerolysin selection to expand glycosylphosphatidylinositol-anchor deficient T lymphocytes , and PIG-A gene sequencing assays to identify and ...

    Research Article last updated 07/20/2018 - 5:14pm.

  10. Therapeutic targeting of NOTCH signaling ameliorates immune-mediated bone marrow failure of aplastic anemia.

    ... remain ill defined. The NOTCH signaling pathway mediates Th1 cell differentiation in the presence of polarizing cytokines, an action ... that expression of both intracellular NOTCH1IC and T-BET, a key transcription factor regulating Th1 cell differentiation, was ...

    Research Article last updated 07/20/2018 - 5:15pm.